Effects of Brexit on medicinal products in Poland

Published date20 December 2018
Law FirmHogan Lovells
AuthorCelina Bujalska
Subject MatterMedical Devices,Life Sciences,EU,Medical Reimbursement,Biosimilars,Regulatory Standards,UK,Poland,Member State,UK Brexit,Pharmaceutical Industry,No-Deal Brexit

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT